u/egfr_watcher

my creatinine ticked up during rapid loss and settled. hydration confounds everything at the individual level, which is exactly why trial-level slope data matters and my n=1 does not.

the parallel with the renal endpoints is worth drawing. both are cases where the hard endpoint is expensive and the cheap proxy is noisy at the individual level.

The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

Right. And a blank between injections settles the carryover argument before it starts.

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

Right. And a blank between injections settles the carryover argument before it starts.

Resolution between two peaks depends on retention, selectivity and efficiency.

Agreed. And the corollary is that the method line on a certificate is not decoration, it is the number’s provenance.

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Reading the trial literature on this without misleading yourself.

Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.

Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.

Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.

Cash pricing, which people skip because they assume coverage is the only route.

Prices at the counter vary between pharmacies, sometimes substantially, in the same city. Members here have found spreads worth a real amount per month by ringing four places and asking for the cash price of a specific presentation.

That does not make coverage unimportant. It does mean that while an authorization is in process — which can take weeks — knowing the actual cash spread is worth half an hour of phone calls. Post what you find with the province and the month; the comparison threads here work for exactly the same reason the UK pricing tracker does.

Careful — that is a dosing intuition carried over from another board and there is no basis for it here.

formulary decisions are provincial, so the province is the first fact

I would not read one pharmacy’s cash price as the going rate. The spread is real.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

axis labels or the trace is decoration

you cannot report to two decimals off that baseline

Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.

private plans and provincial plans are different fights entirely

integration decisions move the number more than the sample does

private plans and provincial plans are different fights entirely

ghost peak, check the plumbing first, it is always the plumbing

axis labels or the trace is decoration

Disagree.

zeynep_zielinski is right — the integration choice is a decision and it should be stated alongside the result.

Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.

Why two honest labs report different numbers on the same vial.

Start with the gradient. A shallower slope holds compounds on the column longer and usually separates close-eluting species better. A steeper one gets you a faster run and a fatter peak. If a related substance elutes near the main peak, one method resolves it and reports it separately, the other absorbs part of it into the main peak.

Then integration. Where the baseline is drawn under a shoulder is a decision made by a person or by a piece of software configured by a person. It moves the number.

A point or two of spread between services on this assay is ordinary. Treating one lab as ground truth is how people end up in arguments with suppliers that neither side can win.

satiety signalling rather than incretin signalling

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

LC-MS for identity, UV for relative quantity

Is there a quantity limit involved rather than a coverage refusal?

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

The honest state of the evidence on this board, since somebody should write it down.

Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.

Spent three weeks on what turned out to be a quantity limit rather than a coverage question.

system suitability before you believe any number on the run

Which province?

axis labels or the trace is decoration